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Purpose: Pregnancy and the puerperium are time periods of an increased risk for venous thromboembolism. An ideal
treatment should lead to complete restoration of the venous lumen, elimination of the embolic source, and prevention of
severe postphlebitic syndrome. Anticoagulation therapy with heparin or thrombectomy are treatment options. In the
current literature, these options are discussed controversially.
Methods: From January 1982 to December 2001, 97 women underwent (93% transfemoral) thrombectomy and
construction of an arteriovenous fistula (AVF) for deep venous thrombosis related to pregnancy. The clinical and
coagulation parameters were evaluated. The AVF was ligated 3 to 6 months later. Follow-up with duplex ultrasound scan,
photoplethysmography, and strain-gauge plethysmography was completed in 87 women.
Results: Surgery was performed without any maternal death or pulmonary embolization. A cesarean section was carried
out during the same anesthesia in 11 cases. Thrombectomy was completed with construction of a temporary AVF in 90
patients (92.8%). One fetal death occurred in the recovery room for unknown reasons. In the early postoperative course,
16 patients (16.5%) underwent redo surgery for rethrombosis with or without the occlusion of the fistula. In 14 of these
patients, the venous system remained patent thereafter. Fetal or neonatal death occurred in five cases 2 to 10 weeks after
surgery, mainly because of abruption of the placenta probably from anticoagulation. Among 247 preoperatively occluded
anatomic regions, 221 could be restored, and the secondary patency rate amounted to 89.5%. After a mean follow-up
period of 6 years, 49 patients (56.3%) were seen without a postphlebitic syndrome, and only three patients (3.5%) had had
a leg ulcer develop.
Conclusion: In experienced hands, venous thrombectomy is a safe method to prevent pulmonary embolism and
postphlebitic syndrome in women during pregnancy and the puerperium. The frequency of a severe postphlebitic
syndrome after our surgical approach is lower than the rates published for anticoagulation treatment alone. (J Vasc Surg
2003;37:528-32.)
Pregnancy and the puerperium are periods of elevated
risk for venous thromboembolism. The prepartum and
peripartum incidence rates of deep venous thrombosis
(DVT) are reported to be about 0.5 to 1.0 per 1000 live
births.1 One of 10 DVTs is complicated by pulmonary
embolism (PE).1,2 In addition to general risk factors for
DVT, a family history of thromboembolic events, acquired
or hereditary thrombophilia,3 and pregnancy-associated
factors, such as immobilization, hyperemesis gravidarum,
amnion infection, placental abruption, hypertension, pre-
eclampsia, and intrauterine growth retardation, have to be
considered.4-6
No consensus exists about the optimal treatment of
patients with pregnancy-associated DVT involving the il-
iofemoral veins, with or without involvement of the inferior
vena cava (IVC), which lead to PE in 10% of cases. In
particular, the role of thrombectomy is discussed contro-
versially. An ideal treatment should lead to a complete
restoration of the venous lumen, elimination of the embolic
source, prevention of severe postphlebitic syndrome (PPS),
and preservation of the vein valve function. Anticoagula-
tion therapy can prevent progression of thrombus and PE.
Recanalization with heparin treatment has been demon-
strated but is rare and unpredictable. It probably reflects a
spontaneous lysis of the thrombus. Fibrinolysis seems to be
the ideal treatment. Not only thrombi in the deep veins
may be dissolved, but pulmonary emboli can be reached as
well. However, fibrinolysis is associated with severe com-
plications and contraindications.
PATIENT POPULATION AND METHODS
Six hundred sixty patients with DVT were treated with
venous thrombectomy in our department during the last
18 years, among them 97 pregnant or puerperal women.
The overall average age was 41.3 years (range, 14 to 77
years); the average age of the subgroup (n  97) was only
22.0 years (range, 17 to 41 years).
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A retrospective review of all patient files from 1982 to
1996 and a prospective study from April 1996 to December
2001 were performed to collect all data from patients with
thromboembolic events during pregnancy and after deliv-
ery. Medical history, pregnancy-related complications, and
hereditary and acquired coagulation risk factors were re-
ported.
Most of the thromboembolic events was diagnosed in
the third trimester, with 39.1%, and in the early postpartum
period, with 29.9% (Figure). The onset of symptoms was
within 10 days before surgery in nearly 75% and in more
than 10 days in 15%, and in 10% of the patients, no
information was available about the onset. Twelve percent
had symptoms or a positive computed tomographic (CT)
scan of PE previous to admission to our department.
We assessed the anatomy of DVT in each woman
selected for surgery by describing the extension into various
anatomic regions with phlebography and duplex scan re-
sults. Additional CT scans were performed to exclude an
involvement of the IVC in 20 patients. In 19 patients
(19.6%), the thrombosis extended from the IVC, and in 78
patients (80.4%), from the iliac veins to distal regions
(Table I). On average, patients had more than 2.5 regions
(total, 247 regions) affected. In all cases, a thrombectomy
was performed and, except for seven women, completed
with the construction of an arteriovenous fistula (AVF),
usually in the groin. The fistula was constructed with the
femoral artery or popliteal artery and a side branch of the
greater saphenous vein, but not below the tibiofibular
trunk to achieve sufficient flow.
The most frequent risk factor among the patient group
was a pregnancy-related immobilization in 49 individuals
(50.5%), followed by a familial history of DVT in 12
patients (12.4%) and hereditary risk factors (factor V Lei-
den) in five patients (5.2%). Nearly all patients were referred
to our department from outside hospitals. In some in-
stances, a primary therapy had already been initiated. Six
percent (n  6) had already undergone unsuccessful fibri-
nolysis and 2.1% (n  2) unsuccessful thrombectomy be-
fore admission to our department.
An experienced obstetrician was present at the time of
thrombectomy, during which the fetal heart rate was mon-
itored continuously. In the prospective part of the study, all
pregnant women scheduled for surgery before 34 weeks of
gestation received induction of lung maturity.
The operative technique included interruption of the
blood flow exclusively with vessel loops in a tourniquet
fashion and longitudinal venotomy (because transverse
venotomy does not allow to inspect and to thrombecto-
mize all adjacent veins). To avoid PE, a Fogarty catheter
(8F to 14F) was placed into the IVC before a second
catheter was used for thrombectomy. If the thrombosis
extended into the IVC, the protective catheter was inserted
through the greater saphenous vein from the contralateral
Thrombotic events during pregnancy and after delivery. pp, Postpartum.
Table I. Anatomical involvement
Anatomical regions No.
IVC 3 (3.1%)
IVC  IV 3 (3.1%)
IVC  IV  FV 4 (4.1%)
IVC  IV  FV  PV 1 (1.0%)
IVC  IV  FV  PV  CV 8 (8.3%)
IV 12 (12.4%)
IV  FV 46 (47.4%)
IV  FV  PV 10 (10.3%)
IV  FV  PV  CV 10 (10.3%)
Total 97 (100%)
IV, Iliac vein; FV, femoral vein; PV, popliteal vein; CV, crural vein.
Table II. Localization of AVF
Localization No.
Inguinal
Unilateral 70 (75.2%)
Bilateral 9 (9.3%)
Adductor channel 6 (6.2%)
Popliteal 5 (5.2%)
No fistula 7 (7.1%)
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side. Manual and rubber band compression thrombectomy
was performed for distal thrombosis. Before discharge,
every patient was examined with duplex or CT scan. An
inguinal incision was used in 90 patients (92.8%), a trans-
peritoneal-inguinal incision in three patients (3.1%), and a
laparotomy exclusively in four patients (4.1%). A simulta-
neous cesarean section was scheduled in 11 women
(11.3%). In one patient, an inflammatory ovarian vein had
to be resected. The AVF was closed within 6 months after
thrombectomy. Anticoagulation therapy with low–molec-
ular weight heparin was administered in women during
pregnancy until delivery and then switched to warfarin
sodium. In women with DVT after delivery, we started
warfarin sodium therapy at the first day after surgery. Anti-
coagulation therapy ended 3 months after AVF closure.
All patients were invited for a follow-up examination
after the study protocol. Duplex scan, photoplethysmogra-
phy, and strain-gauge plethysmography were performed
after 6 weeks, every 3 months, and yearly to check the
patency of the deep veins and the valve function. Blood
samples were taken to determine factor V Leiden
(G1691A), prothrombin mutation (G20210A), methyltet-
rahydrofolate reductase polymorphism (G677T), reduced
levels of antithrombin III, protein S, and protein C.
RESULTS
No patient died during surgery. Moreover, no pulmo-
nary embolization was detected with pulmonary artery
catheter, which was used routinely. One fetus died in the
recovery room for unknown reasons. In most of our pa-
tients (84.5%), the AVF was constructed in the groin
(Table II). Seven patients received no AVF because the
DVT was estimated to be not older than 5 days and limited
to only one anatomic region. No rethrombosis occurred in
these cases.
In 16 patients (16.5%), rethrombosis occurred before
scheduled discharge. All of these 16 patients underwent
successful reoperation, with 14 complete and two partial
restorations of the lumen. A small PE in three patients
(3.1%) and a heparin-induced thrombocytopenia type II in
four patients (4.1%) were diagnosed in the postoperative
period. Three patients (3.1%) had pneumonia develop after
preoperative PE. The postoperative duplex scan or the CT
scan showed a complete restoration of the lumen in 88
patients (90.7%). Of 247 anatomic regions occluded before
surgery, patency was restored in 221 (secondary patency
rate, 89.5%).
Five neonates or fetuses of women with continuing
pregnancy after thrombectomy died in utero or perinatally
2 to 10 weeks after surgery. The main reason was an
abruption of the placenta probably from anticoagulation
therapy (Table III).
Eighty-seven of 97 patients (89.7%) were examined
routinely after 6 weeks, 3 months, and 6 months and then
once a year for follow-up in our outpatient clinic. The mean
follow-up period was 70.5 months.
Forty-nine women (56.3%) had no symptoms of PPS,
31 (35.6%) showed only mild symptoms, and four patients
(4.6%) had severe PPS. Ulceration occurred in three pa-
tients (3.5%) after surgery within 24 months (Table IV).
During the observation period, a second episode of
DVT occurred in 10 patients (11.5%) and DVT combined
with PE in one woman. In the case with DVT and PE,
surgery was performed successfully again. The other pa-
tients underwent anticoagulation therapy because the DVT
was limited to the veins below the inguinal ligament.
Table V summarizes the risk factors in our patients
compared with an age-matched group of healthy volun-
teers. The highest relative risk was found for prothrombin
mutation (odds ratio, 11.4) followed by factor V Leiden
(odds ratio, 7.7). Risk estimations for deficiencies of anti-
thrombin, protein C, and protein S were valid only for mild
deficiencies.
DISCUSSION
Heparin is the conventional treatment for DVT during
pregnancy, but it can cause complications.6 Bleeding,
spontaneous bone fractures, and heparin-induced throm-
bocytopenia type II are the major complications of antico-
agulation therapy.7 Rutherford and Phelan8 reported a 5%
to 30% maternal complication rate for anticoagulation
treatment, and Ginsberg9 reported a 2.6% fetal mortality
Table IV. Long-term results: PPS after mean
observation period of 6 years (range, 0.5 to 16.5 years)
CEAP class No.
No PPS 0 49 (56.3%)
Mild PPS 1-2 31 (35.6%)
Severe PPS 3-4 4 (4.6%)
Venous ulcer 5-6 3 (3.5%)
Table III. Intrauterine or perinatal death after thrombectomy during long-term anticoagulation therapy
Gestation week Treatment Death after Cause
Case 12 (gemini) 27 wks Previous lysis 
thrombectomy
2 wks Placental abruption
Case 3 24 wks Thrombectomy 10 wks Placental abruption
Case 4 25 wks Thrombectomy 10 wks Imminent demise and
placental abruption
Case 5 30 wks Thrombectomy 4 wks Imminent demise and
placental abruption
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rate. In our patient group, the surgery-related fetal mortal-
ity rate was 1.8% (1/53). During long-term anticoagula-
tion therapy after thrombectomy, five fetal deaths oc-
curred, mainly caused by abruption of the placenta or
imminent demise. Heparin treatment can most probably
avoid thrombus progression and reduce the risk for PE but
does not restore the vascular lumen.
Theoretically, fibrinolysis appears favorably because not
only thrombi in the deep veins may be dissolved but pul-
monary emboli can be reached as well. However, the risk of
severe bleeding precludes its use during pregnancy.10
Consequently, surgical restoration of the deep venous
system is an attractive alternative. There are two key points
to success (ie, the special surgical technique and the AVF).
The technique of venous thrombectomy is different from
arterial thrombectomy as described before.11 The fistula
increases blood velocity through the thrombectomized
veins and causes an elevation of venous pressure and con-
tinuous flow even at times of maximal inspiration. In our
opinion, the anatomic approach, the exclusive use of vessel
loops, and the location of the AVF are contributing ele-
ments to a favorable outcome. In our study, no pregnant
women died and no intraoperative PE occurred. This
shows the safety of surgical treatment of DVT in pregnan-
cy.11 In the literature, the frequency of PPS after anticoag-
ulation therapy during pregnancy is quoted between 60%
and 78%. After surgical treatment and consecutive antico-
agulation therapy, the frequency of PPS is approximately
40% (Table VI).
Thromboembolic events are major causes of maternal
mortality.12 It is important to identify patients at risk.
Knowledge about genetic factors for thrombosis allows
administration of a risk- adapted treatment for prevention
of rethrombosis and recurrent PE.3,13-15 Anticoagulation
therapy with heparin followed by warfarin sodium can
usually be terminated after 6 to 12 months if there is no
residual indication for long-term anticoagulation. In these
patients at high risk, heparin prophylaxis should be insti-
tuted during further episodes predisposing to thrombosis
(eg, immobilization, surgery, another pregnancy).
In summary, venous thrombectomy is a safe method to
prevent PE and recurrent thromboembolic events, even in
women during pregnancy and after delivery. According to
our criteria, surgical removal of the thrombi was indicated
in patients with massive painful blue edema, DVT extend-
ing above the inguinal ligament, proximal thrombi not
adherent to the vein wall as documented with duplex scan
or CT scan studies, previous PE, and the involvement of the
IVC and bilateral iliac veins. Maternal and fetal complica-
tions are comparable with those with heparin treatment.
Thrombectomy in combination with a temporary AVF can
restore venous lumen completely (in our patients, 90.7%)
and safely in patients with massive DVT, thereby reducing
the risk of PPS (in our patients, C3-6, 8.1%). However, this
delicate surgery should remain in the hands of experts
specialized in surgery of the deep veins. We need further
studies to compare the results of thrombectomy (regarding
PE, PPS, patency, and recurrent DVT) with other treat-
ment.
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